Skip to content

Definium Therapeutics

US · DFTX #2132 by market cap Listed 1970
28.34 -1.14 -3.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 28.81 -2.27%
After-hours 28.05 -1.02%
48.4522.8628.342026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on DFTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +61.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 7.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -64.1% Better than 8%
Return on invested capital -59.5% Better than 5%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -36.9% Better than 13%
6-month return 26.0% Better than 87%
12-month return (ex latest month) 234.0% Better than 99%
Distance below 52-week high 43.0% Better than 25%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.3x Better than 90%
Debt to assets 9.2% Better than 71%
Interest coverage -32.5x Better than 8%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 162.2% Better than 91%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.66%
1M -19.24%
3M -37.58%
6M +35.79%
YTD +111.65%
1Y +160.48%
3Y +930.55%
5Y -13.73%

Key statistics

Price & volume

Prev close
29.48
Open
29.14
Day range
28.18 - 29.51
Avg price
28.86
Volume
3.24M
Turnover
93.44M
Amplitude
4.51%
52-week range
10.53 - 49.70

Valuation

P/E
-13.76
P/E (TTM)
-9.71
P/B
4.01
EPS
-2.06
Net profit
-282.01M
Net assets
968.02M

Share structure

Market cap
3.88B
Float cap
3.63B
Shares out
136.90M
Float shares
128.19M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 45% of range
10.53 49.70

43.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+36.58M net over the window

Short interest

Shares short
9.61M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Definium Therapeutics (DFTX)?

Definium Therapeutics last traded at 28.34. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Definium Therapeutics's market cap?

About 3.88B.

What is the P/E ratio of Definium Therapeutics?

The trailing twelve-month P/E is -9.71. The Valuation tab shows it against the stock's own five-year range.

Does Definium Therapeutics pay a dividend?

Definium Therapeutics does not currently pay a regular dividend.

Is Definium Therapeutics a buy according to analysts?

The consensus of 14 analysts is a Buy rating, with an average 12-month price target of 74.31, which implies 162.2% upside from the current price. This is not investment advice.

What is Definium Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Definium Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Definium Therapeutics discussion 0 comments

Add a comment